GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cartesian Therapeutics Inc (NAS:RNAC) » Definitions » PB Ratio

Cartesian Therapeutics (Cartesian Therapeutics) PB Ratio : (As of Apr. 29, 2024)


View and export this data going back to 2016. Start your Free Trial

What is Cartesian Therapeutics PB Ratio?

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2024-04-29), Cartesian Therapeutics's share price is $21.03. Cartesian Therapeutics's Book Value per Share for the quarter that ended in Dec. 2023 was $-81.55. Hence, Cartesian Therapeutics's PB Ratio of today is .

The historical rank and industry rank for Cartesian Therapeutics's PB Ratio or its related term are showing as below:

During the past 10 years, Cartesian Therapeutics's highest PB Ratio was 1605.41. The lowest was 1.63. And the median was 4.68.

RNAC's PB Ratio is not ranked *
in the Biotechnology industry.
Industry Median: 2.375
* Ranked among companies with meaningful PB Ratio only.

During the past 12 months, Cartesian Therapeutics's average Book Value Per Share Growth Rate was -543.40% per year. During the past 3 years, the average Book Value Per Share Growth Rate was -153.60% per year.

During the past 10 years, the highest 3-Year average Book Value Per Share Growth Rate of Cartesian Therapeutics was 84.70% per year. The lowest was -153.60% per year. And the median was -0.35% per year.

Back to Basics: PB Ratio


Cartesian Therapeutics PB Ratio Historical Data

The historical data trend for Cartesian Therapeutics's PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cartesian Therapeutics PB Ratio Chart

Cartesian Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 24.47 - 17.90 1.84 -

Cartesian Therapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.84 2.86 2.63 2.72 -

Competitive Comparison of Cartesian Therapeutics's PB Ratio

For the Biotechnology subindustry, Cartesian Therapeutics's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cartesian Therapeutics's PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cartesian Therapeutics's PB Ratio distribution charts can be found below:

* The bar in red indicates where Cartesian Therapeutics's PB Ratio falls into.



Cartesian Therapeutics PB Ratio Calculation

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.

Cartesian Therapeutics's PB Ratio for today is calculated as follows:

PB Ratio=Share Price/Book Value per Share (Q: Dec. 2023)
=21.03/-81.552
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.


Cartesian Therapeutics  (NAS:RNAC) PB Ratio Explanation

Unlike valuation ratios relative to the earning power such as PE Ratio, PE Ratio without NRI, PS Ratio, Price-to-Operating-Cash-Flow , or Price-to-Free-Cash-Flow, the PB Ratio measures the valuation of the stock relative to the underlying asset of the company.

The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.


Cartesian Therapeutics PB Ratio Related Terms

Thank you for viewing the detailed overview of Cartesian Therapeutics's PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Cartesian Therapeutics (Cartesian Therapeutics) Business Description

Traded in Other Exchanges
Address
65 Grove Street, Watertown, MA, USA, 02472
Cartesian Therapeutics Inc is a clinical-stage biopharmaceutical company. The company uses its ImmTOR immune tolerance platform, which is designed to give rise to antigen-specific immunity, mitigating unwanted immune responses. Its product pipeline includes MMA-101, SEL-212 for Chronic Severe Gout, SEL-313 for Ornithine Transcarbamylase Deficiency (OTC), and others.
Executives
Carsten Brunn director, officer: President & CEO C/O SELECTA BIOSCIENCES, INC., 480 ARSENAL WAY, WATERTOWN MA 02472
Peter G Traber officer: Chief Medical Officer 430 THAMER LANE, HOUSTON TX 77025
Takashi Kei Kishimoto officer: Chief Scientific Officer 480 ARSENAL ST., BUILDING ONE, WATERTOWN MA 02472
Lloyd P. Johnston officer: COO and SVP, R&D 480 ARSENAL ST., BUILDING ONE, WATERTOWN MA 02472
Blaine Davis officer: Chief Financial Officer C/O ARTARA THERAPEUTICS, INC., 1 LITTLE WEST 12TH STREET, NEW YORK NY 10014
Carrie Smith Cox director SCHERING-PLOUGH CORPORATION, 2000 GALLOPING HILL ROAD, KENILWORTH NJ 07033
Timothy C Barabe director C/O ARQULE, INC., 1 WALL STREET, 6TH FLOOR, BURLINGTON MA 01803
Timothy A Springer director 36 WOODMAN ROAD, CHESTNUT HILL MA 02467
Kevin Tan officer: Chief Financial Officer 20 HICKORY ROAD, WELLESLEY MA 02482
Nishan M Desilva director 11119 NORTH TORREY PINES RD STE 200, LA JOLLA CA 92037
Ann K. Donohue officer: VP Finance C/O SELECTA BIOSCIENCES, INC., 480 ARSENAL WAY, BUILDING ONE, WATERTOWN MA 02472
Bradford D. Dahms officer: Chief Financial Officer C/O SELECTA BIOSCIENCES, INC., 480 ARSENAL WAY, WATERTOWN MA 02472
Goran Ando director
Scott Dunseth Myers director C/O CASCADIAN THERAPEUTICS, INC., 3101 WESTERN AVE., SUITE 600, SEATTLE WA 98121
Elona Esq. Kogan officer: General Counsel C/O SEER, INC., 3800 BRIDGE PARKWAY, SUITE 102, REDWOOD CITY CA 94065

Cartesian Therapeutics (Cartesian Therapeutics) Headlines

From GuruFocus

Selecta Biosciences to Participate at the SVB Securities Global Biopharma Conference

By Stock market mentor Stock market mentor 02-07-2023

Selecta Biosciences Announces $38.7 Million Underwritten Offering

By GuruFocusNews GuruFocusNews 04-06-2022